Equillium, Inc.
EQ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001746466
No open-market purchases or sales by Equillium, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $133.0M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Equillium, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- −2 vs. Q4 2024
- Shares held
- 8.66M
- −45.5K (−0.5%) vs. Q4 2024
- Total value
- $3.39M
- −$3.13M (−48.0%) vs. Q4 2024
- New holders
- 2
- 6 more added
- Sold out
- 4
- 6 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EQ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 60 | $133.0M |
| Q1 2026 | 50 | $81.0M |
| Q4 2025 | 36 | $54.7M |
| Q3 2025 | 40 | $42.4M |
| Q2 2025 | 27 | $2.74M |
| Q1 2025 | 24 | $3.39M |
| Q4 2024 | 26 | $6.52M |
| Q3 2024 | 26 | $7.25M |
| Q2 2024 | 25 | $6.15M |
| Q1 2024 | 28 | $20.5M |
| Q4 2023 | 25 | $6.85M |
| Q3 2023 | 25 | $6.75M |
| Q2 2023 | 27 | $7.44M |
| Q1 2023 | 28 | $7.86M |
| Q4 2022 | 31 | $13.3M |
| Q3 2022 | 30 | $28.4M |
| Q2 2022 | 25 | $25.6M |
| Q1 2022 | 30 | $39.7M |
| Q4 2021 | 26 | $27.0M |
| Q3 2021 | 22 | $49.9M |
| Q2 2021 | 28 | $41.9M |
| Q1 2021 | 33 | $54.6M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Equillium, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Decheng Capital LLC | 4,447,308 | $1.74M | 0.49% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 1,824,977 | $711.7K | 4.40% | 00.0% | Unchanged |
| Vanguard Group Inc | 841,948 | $330.0K | 0.00% | 00.0% | Unchanged |
| Cota Capital Management, LLC | 562,278 | $220.6K | 100.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 269,500 | $105.7K | 0.00% | +8,100+3.1% | Added |
| Geode Capital Management, LLC | 205,367 | $80.6K | 0.00% | +982+0.5% | Added |
| Acadian Asset Management LLC | 108,691 | $40.0K | 0.00% | 00.0% | Unchanged |
| Callan Capital, LLC | 99,688 | $39.1K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 59,720 | $23.4K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 55,649 | $21.8K | 0.00% | +55,649 | New |
| DCF Advisers, LLC | 39,492 | $15.5K | 0.01% | −23,455−37.3% | Reduced |
| BlackRock, Inc. | 36,967 | $14.5K | 0.00% | −702−1.9% | Reduced |
| Northern Trust Corp | 35,019 | $13.7K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 25,000 | $10.0K | 0.00% | 00.0% | Unchanged |
| Tritonpoint Wealth, LLC | 13,500 | $5.30K | 0.00% | +13,500 | New |
| Virtu Financial LLC | 13,954 | $5.00K | 0.00% | −1,735−11.1% | Reduced |
| Morgan Stanley | 10,238 | $4.02K | 0.00% | +3,353+48.7% | Added |
| Tower Research Capital LLC (TRC) | 6,819 | $2.67K | 0.00% | +856+14.4% | Added |
| UBS Group AG | 1,722 | $675 | 0.00% | −15,587−90.1% | Reduced |
| Wells Fargo & Company | 1,000 | $392 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 865 | $339 | 0.00% | +100+13.1% | Added |
| Bank of America Corp | 151 | $59 | 0.00% | +6+4.1% | Added |
| JPMorgan Chase & Co | 38 | $15 | 0.00% | −3−7.3% | Reduced |
| Simplex Trading, LLC | 1,495 | $0 | 0.00% | −595−28.5% | Reduced |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −41,644−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −19,754−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −13,538−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |